Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) is pleased to announce that, on 31 May 2022, the Drug Registration Certificate for in-licensed product Teglutik® (Riluzole Oral Suspension) has been obtained from the China National Medical Products Administration (NMPA). Teglutik® has been approved to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (“ALS”).

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) is pleased to announce that, the Drug Registration Certificate for in-licensed product Natulan® (Procarbazine Capsules) has been obtained from the China National Medical Products Administration (“NMPA”). Natulan® has been approved for use in combination with other anticancer drugs to treat Hodgkin’s Lymphoma (“HL”).

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) announced that, the registration of in-licensed product “Nitric Oxide for Inhalation” (INOmax®) was approved for commercialization by China National Medical Products Administration (NMPA). INOmax®, the first medicinal gas product approved in China, is an inhaled nitric oxide pharmaceutical for treating term and near-term neonates (>34weeks) with hypoxic respiratory failure ("HRF") associated with pulmonary hypertension (PPHN). It is indicated to improve oxygenation and reduce the need for extra-corporeal membrane oxygenation (ECMO) of patients.

Hong Kong, March 22, 2022, the Retail Sales Department of the Group Commercial Operations Centre, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”) signed the Comprehensive Strategic Cooperation Agreement with Guangdong Rongtai Pharmaceutical Company Limited (“Rongtai Pharmaceutical”).

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”) aims at expanding the distribution channels and offering wide array of health and pharmaceutical products to meet the variety of needs. The Group launched the flagship store on Ali’s and Jingdong’s e-commerce platforms in China on March 23, 2022. Dr. Li Xiaoyi, the founder and Ms. Leelalertsuphakun Wanee, the Managing Director of the Group joined the Virtual Grand Opening Ceremony of Lee’s Pharm Flagship Store held in Guangzhou Sales Office. By establishing Lee’s Pharm flagship store, the Group has reached a new milestone with the development of new retail and is looking forward to connecting the public and the patients in needed.

Recently, the Anhui Provincial Department of Economy and Information Technology announced the list of “Anhui Provincial Role Model Enterprise in Consumer Products Industry” through online platform. Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke-Hefei”), the subsidiary of Lee’s Pharmaceutical Holdings Limited was one of the few pharmaceutical companies to receive this honour.

Hong Kong, December 23, 2021, the “2020-2021 Top Brand List of Family Choice Pharmacy in China”, jointly organized by familydoctor.com.cn and Sinomonitor, was officially announced through online platform. Two of the signature products from Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”) are granted admission into the guidance list. The in-licensed product Ferplex® and the in-house proprietary product Yallaferon®, are listed in the “Health Supplement Category” and “Gynecological Category” respectively.

Hong Kong, December 23, 2021, the “STEM Experience Program for Secondary Students—Kanya Lee Scholarship Recognition Ceremony” was successfully held in Cordis Hotel, Hong Kong. The founder and Non-Executive Director, Dr. Li Xiaoyi, the Chairman, Ms. Lee Siu Fong and the Managing Director, Ms. Leelalertsuphakun Wanee of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”) were invited to attend the ceremony and witnessed the establishment of “Kanya Lee Class Reunion”.

Hong Kong, December 18, 2021, the 8th General Assembly and 2021 Annual Meeting of China Pharmaceutical Industry Association was held successfully in Jiangxi building, Beijing. Yallaferon® , Interferon α2b Gel, the in-house proprietary product of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”) was honoured with “2021 Biopharmaceutical Excellent Brand” Award.

Dr. Li Xiaoyi, the founder and Non-Executive Director of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”) was recognized as an Exceptional Talent in Guangzhou Nansha New Zone (Free Trade Zone), with an award certificate of merit in the High-Level Talents.

Face mask has become an essential item for COVID-19 prevention. To fulfill commitments to corporate social responsibility, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”) collaborated with Caritas Hong Kong to donate a total of one million masks to support the community. The donation campaign was undertaken jointly with associated units of Caritas Family Service and religious organizations to distribute to the underprivileged groups and local schools between 1st and 16th December 2021.

Hong Kong, September 10, 2021, an award ceremony of 2020 Guangzhou Unicorn Innovative Company was successfully held in Tiande Plaza, Guangzhou. The subsidiary of Lee’s Pharmaceutical Holdings Limited - Zhaoke Oncology was invited to attend the ceremony and honoured with the “2020 Guangzhou High-end, Precision and Sophisticated Firms” Award.